F S&P 500
5,258.25 +19.25 (+0.37%) F Dow Jones
39,653.00 +117.00 (+0.30%) F Nasdaq
18,296.75 +82.25 (+0.45%) E-mini Russell 2000 Index Futur
2,093.30 +9.20 (+0.44%) Petróleo
79.91 +0.65 (+0.82%) Oro
2,383.90 +43.60 (+1.86%)
4SC AG (VSC.F)
4SC AG
Fraunhoferstraße 22
Planegg 82152
Germany
49 89 700 763 0
https://www.4sc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 13
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jason Loveridge B.Sc., FRSM, Ph.D. | Chairman of Management Board, CEO & MD | 519k | N/D | N/D |
| Ms. Kathleen Masch-Wiest | COO & Member of the Management Board | N/D | N/D | N/D |
| Ms. Anna Niedl Ph.D. | Corporate Communications & Investor Relations Officer | N/D | N/D | N/D |
| Dr. Susanne Danhauser-Riedl M.D. | Chief Medical Officer | N/D | N/D | N/D |
| Ms. Larissa Stuttem | Team Assistant | N/D | N/D | N/D |
Descripción
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
Gestión corporativa
La calificación ISS Governance QuickScore de 4SC AG a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
